Clinical Trial

A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia

Enrolling by Invitation Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test the potential benefits of BHV-7000 in reducing chronic pain in participants with IEM with a previously demonstrated gain of function mutation in the SCN9A gene.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06 -> 2026-11 2026-04-09
minor Completion pushed: 2026-07 -> 2026-11 2026-04-09
Trial Details
NCT Number NCT07262268
Lead Sponsor Biohaven Therapeutics Ltd.
Conditions Familial Erythromelalgia
Enrollment 5 participants
Start Date 2026-01-15
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-04-08